These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 32978858)
1. Empiric vs screening-based use of isoniazid for tuberculosis prophylaxis: Safety and effectiveness in lung transplant recipients in Saudi Arabia. Korayem GB; Alissa DA; AlSuhaibani NI; AlSwailem GS; AlShammari MA; Yaqoob I; Aljasser DS; Almaghrabi RS Transpl Infect Dis; 2021 Apr; 23(2):e13473. PubMed ID: 32978858 [TBL] [Abstract][Full Text] [Related]
2. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area. Moon HH; Park SY; Kim JM; Park JB; Kwon CHD; Peck KR; Kim SJ; Lee SK; Joh JW Ann Transplant; 2017 Jun; 22():338-345. PubMed ID: 28579606 [TBL] [Abstract][Full Text] [Related]
3. The efficacy of isoniazid prophylaxis in renal transplant recipients in a high tuberculosis burden country. Dodani SK; Nasim A; Aziz T; Naqvi A Transpl Infect Dis; 2021 Oct; 23(5):e13709. PubMed ID: 34331355 [TBL] [Abstract][Full Text] [Related]
4. Use of isoniazid chemoprophylaxis in renal transplant recipients. Naqvi R; Naqvi A; Akhtar S; Ahmed E; Noor H; Saeed T; Akhtar F; Rizvi A Nephrol Dial Transplant; 2010 Feb; 25(2):634-7. PubMed ID: 19783599 [TBL] [Abstract][Full Text] [Related]
5. Management and outcome of latent tuberculosis in living renal transplant donors. Habhab WT; Alraddadi BM; Idris N; Alghamdi S; Zabani N; Fahmy A; Malik AA; Alwaassia M Saudi J Kidney Dis Transpl; 2019; 30(1):151-152. PubMed ID: 30804276 [TBL] [Abstract][Full Text] [Related]
6. Isoniazid prophylaxis in liver transplant recipient with latent tuberculosis: Is it harmful for transplanted liver? Ghayumi SMA; Shamsaeefar A; Motazedian N; Mashhadiagha A; Sayadi M; Nikeghbalian S; Malekhosseini SA Transpl Infect Dis; 2022 Aug; 24(4):e13849. PubMed ID: 35579604 [TBL] [Abstract][Full Text] [Related]
7. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397 [TBL] [Abstract][Full Text] [Related]
9. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy? Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811 [TBL] [Abstract][Full Text] [Related]
10. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda. Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788 [TBL] [Abstract][Full Text] [Related]
13. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Currie AC; Knight SR; Morris PJ Transplantation; 2010 Oct; 90(7):695-704. PubMed ID: 20647975 [TBL] [Abstract][Full Text] [Related]
14. Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy. Kaptan Y; Suner A; Taş MN; Oksel F; Aksu K; Sayiner A Clin Rheumatol; 2021 Sep; 40(9):3783-3788. PubMed ID: 33745083 [TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis in solid organ transplantation: incidence before and after expanded isoniazid prophylaxis. Al-Mukhaini SM; Al-Eid H; Alduraibi F; Hakami HI; Talhi HA; Shoukri M; Ahmed AM; Ahmed Y; Alrajhi AA Ann Saudi Med; 2017; 37(2):138-143. PubMed ID: 28377543 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of isoniazid prophylaxis in renal allograft recipients. Naqvi R; Akhtar S; Noor H; Saeed T; Bhatti S; Sheikh R; Ahmed E; Akhtar F; Naqvi A; Rizvi A Transplant Proc; 2006 Sep; 38(7):2057-8. PubMed ID: 16979998 [TBL] [Abstract][Full Text] [Related]
18. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. Sterling TR; Brehm WT; Moore RD; Chaisson RE Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327 [TBL] [Abstract][Full Text] [Related]
19. A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants. LaCourse SM; Richardson BA; Kinuthia J; Warr AJ; Maleche-Obimbo E; Matemo D; Cranmer LM; Mecha J; Escudero JN; Hawn TR; John-Stewart G Clin Infect Dis; 2021 Jul; 73(2):e337-e344. PubMed ID: 32564076 [TBL] [Abstract][Full Text] [Related]
20. Role of interferon-gamma release assay for screening and monitoring of latent tuberculosis infection in kidney transplant recipients. Bruminhent J; Treekajonsak T; Kantachuvesiri S; Setthaudom C; Sukkasem W; Kawamatawong T BMC Infect Dis; 2024 Oct; 24(1):1110. PubMed ID: 39375585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]